Kala Bio (KALA) Current Assets (2016 - 2026)
Kala Bio (KALA) posted Current Assets of $12.3 million for Q1 2026, up 29.8% sequentially from $9.5 million in Q4 2025, and down 73.06% YoY from $45.7 million in Q1 2025.
Kala Bio (KALA) Current Assets (2016 - 2026) Analysis & Trends
Kala Bio has reported Current Assets for 11 years, with the latest figure at $12.3 million in Q1 2026.
- Quarterly Current Assets fell 73.06% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (down 73.06% YoY) and the FY2025 annual result came in at $9.5 million, down 82.03% from the prior year.
- Current Assets rose to $12.3 million in Q1 2026 per KALA's latest filing, from $9.5 million in the prior quarter.
- Over five years, Current Assets peaked at $98.3 million in Q1 2022 and troughed at $9.5 million in Q4 2025.
- A 5-year average of $55.2 million and a median of $52.9 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets dropped 0.14% in 2024, then sank 82.03% in 2025.
- Over 5 years, Current Assets stood at $85.9 million in 2022, then plunged by 38.48% to $52.9 million in 2023, then declined by 0.14% to $52.8 million in 2024, then tumbled by 82.03% to $9.5 million in 2025, then increased by 29.8% to $12.3 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $12.3 million, $9.5 million, and $24.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 1.76 Bn |
| 10 | Kala Bio | 9.97 Mn | 9.97 Mn | - | 12.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.32 Mn |
| Dec 31, 2025 | 9.49 Mn |
| Sep 30, 2025 | 24.27 Mn |
| Jun 30, 2025 | 33.66 Mn |
| Mar 31, 2025 | 45.72 Mn |
| Dec 31, 2024 | 52.80 Mn |
| Sep 30, 2024 | 51.28 Mn |
| Jun 30, 2024 | 58.85 Mn |
| Mar 31, 2024 | 50.09 Mn |
| Dec 31, 2023 | 52.87 Mn |
| Sep 30, 2023 | 57.90 Mn |
| Jun 30, 2023 | 65.54 Mn |
| Mar 31, 2023 | 71.34 Mn |
| Dec 31, 2022 | 85.94 Mn |
| Sep 30, 2022 | 84.67 Mn |
| Jun 30, 2022 | 83.52 Mn |
| Mar 31, 2022 | 98.26 Mn |
| Dec 31, 2021 | 124.37 Mn |
| Sep 30, 2021 | 149.09 Mn |
| Jun 30, 2021 | 171.72 Mn |